AMAlfredo Menéndez-Navarro

Alfredo Menéndez-Navarro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alfredo Menéndez-Navarro has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Silicosis in the Artificial Stone Countertop Industry: An Official American Thoracic Society Workshop Report

    by Sheiphali A Gandhi, Gabrielle Y Liu, Jane C Fazio, Olawale Amubieya, Hayley Barnes, Catherine Cavalin, Robert A Cohen, Elizabeth Fireman, Sandra R Garcia, Robert J Harrison, et al.

    Artificial stone–associated silicosis (AS silicosis) has emerged over the past decade as a severe, rapidly progressive, and preventable occupational lung disease affecting workers who manufacture, fabricate, and install artificial stone countertops. Characterized by short latency, accelerated progression, and high morbidity and mortality, AS silicosis disproportionately affects young workers employed in precarious conditions. In response to the growing global burden of disease, this American Thoracic Society workshop was convened in 2025 to review the current state of knowledge regarding AS silicosis, synthesize the current evidence, and identify priorities for research, clinical care, public health surveillance, and prevention. Workshop participants reviewed data spanning exposure science, epidemiology, clinical manifestations, health equity, and policy responses. Evidence demonstrates that artificial stone (AS) dust is highly toxic, containing high concentrations of respirable crystalline silica, resin-derived volatile compounds, and trace metals, resulting in exposures that routinely exceed occupational exposure limits. Despite widespread implementation of wet methods, ventilation, and respiratory protection, hazardous exposures persist across diverse settings globally, highlighting fundamental limitations of existing control strategies. Clinically, AS silicosis is associated with high rates of progressive massive fibrosis, autoimmune disease, infection, respiratory failure, and increasing need for lung transplantation. Treatment options remain limited, underscoring the importance of early detection and exposure cessation. The workshop identified critical gaps in medical screening and public health surveillance worldwide, with inconsistent regulatory frameworks, low compliance, underreporting, and delayed diagnoses. Case detection is often dependent on symptomatic presentation rather than proactive screening, exacerbating disease severity and inequities in care. International experiences illustrate both the consequences of regulatory inaction and the potential impact of decisive interventions, including Australia’s prohibition of crystalline silica–containing artificial stone. This report concludes that AS silicosis represents a failure of primary prevention and calls for coordinated global action. Key priorities include strengthening surveillance systems, ensuring equitable access to screening and care, developing effective therapeutics, advancing exposure science, and implementing higher-order preventive strategies, including the elimination or substitution of high-silica AS. Without urgent and sustained intervention, these products will continue to impose devastating and avoidable harm on workers worldwide.


  • Open Access

    Medicalización y medicamentalización del hambre en la posguerra española

    by Alfredo Menéndez-Navarro, Enrique Perdiguero-Gil, Eduardo Bueno Vergara

    La reciente historiografía sobre el hambre en la posguerra española ha destacado su empleo como forma de represión política y legitimación del régimen. El objetivo de este trabajo es estudiar los procesos de medicalización y medicamentalización del hambre en dicho periodo. Para ello, analizamos la producción médica sobre el hambre del grupo de trabajo de Enríquez Salamanca y exploramos el papel de las prestaciones farmacéuticas del Seguro Obligatorio de Enfermedad para suplir las carencias alimenticias en tiempos de escasez. Ambos procesos contribuyeron a invisibilizar el hambre y sus determinantes sociales y políticos, transformándolos en una cuestión biomédica y asistencial.


  • The Banning of Engineered Stone in Australia: An Evidence-Based and Precautionary Policy

    by Catherine Cavalin, Alfredo Menéndez-Navarro, Alain Lescoat

    On December 13, 2023, Australia became the first country to ban engineered stone. This material contains more than 80 percent crystalline silica, agglomerated with resins, metal oxides and other (potentially toxic) substances. Engineered stone has become a mass-market product since the late 1990s and has contributed to a worldwide resurgence of accelerated forms of silicosis and a notable incidence of systemic diseases. Such a ban is a very rare event in a world where the regulatory framework governing the use of toxic substances in the workplace is generally limited to setting exposure limits. The Australian decision is exemplary in many respects: it is based on public consultation with all stakeholders, it contributes to updating biomedical knowledge that industries seek to conceal or undermine, and it is based on a realistic vision of real working conditions. In the absence of any evidence that lowering the silica content of this material would reduce occupational hazards related to toxic cocktail effects, this ban implements an evidence-based and precautionary public health policy.


  • Open Access

    La prohibición de los aglomerados de cuarzo en Australia, una decisión modélica

    by Alfredo Menéndez-Navarro, Catherine Cavalin

    Australia se convirtió en diciembre de 2023 en el primer país en prohibir el uso de los aglomerados de cuarzo. El consumo de estos materiales sintéticos, que contienen más del 80% de sílice cristalina y que desde los años 90 se han empleado para la fabricación de encimeras de cocina y baños, ha contribuido al resurgimiento en numerosos países de formas aceleradas de silicosis y a una notable incidencia de enfermedades sistémicas. El objeto de este trabajo es analizar los fundamentos que sustentan la decisión australiana. Dichos fundamentos están principalmente recogidos en el informe elaborado en 2023 por la agencia gubernamental Safe Work Australia (SWA), que recomendó la prohibición del producto. SWA llevó a cabo una consulta pública entre todos los actores sociales y científicos interesados en el problema. El informe de SWA señaló la ausencia de evidencia científica sobre un umbral de sílice toxicológicamente seguro cuestionando la estrategia de los fabricantes del material de presentar como productos seguros a los aglomerados con menos del 40% de contenido de sílice. La recomendación de SWA tomó en consideración la evaluación del nivel de cumplimiento de las estrictas medidas de prevención implementadas entre 2019 y 2023, constatando que el incumplimiento siguió siendo generalizado en el sector. Además se realizó un análisis coste-beneficio para valorar el número de casos de silicosis que sería necesario evitar para “compensar” los costes económicos asociados a cada opción de prohibición. Para ello empleó el Valor Estadístico de la Vida (VEV) actualizado en 2023 en Australia y estimó en 4,9 millones de dólares australianos cada vida salvada y silicosis evitada. En nuestra opinión, la prohibición australiana es modélica por la forma en que se ha gestado la decisión, por su sólida fundamentación científica y socio-laboral, y por la aplicación del principio de precaución.


    • 20 December 2023
      • Vol. 97

    [Analysis of Hospital Care Registers due to Silicosis in Spain, 1997-2020].

    by Alfredo Menéndez-Navarro, Catherine Cavalin, Montserrat García-Gómez, Alin Gherasim

    The re-emergence of silicosis in Spain since 2007 has been identified by the increase in the number of occupational disease reports. The aim of our study was to analyse the silicosis care processes attended by the National Health System between 1997 and 2020 to better understand the epidemiological dimension of the problem. Processes were obtained from the Registro de Actividad Sanitaria Especializada (RAE-CMBD), with ICD-9-CM codes 500 and 502 (1997-2016) and ICD-10-CM J60, J62.0 and J62.8 (2017-2020). Descriptive statistical methods and modelling by logistic regression and Joinpoint regression methodology were applied. A total of 111,325 records were obtained (ages twenty-one hundred years), 4.3% for silicosis as the main diagnosis (PD) and 95.7% as a secondary diagnosis (SD). Men accounted for 98% and women for 2%. The mean age for SD processes was 75.1, and 68.7 for PD processes. The median age increased by eight years for SD and decreased by three years for PD. Although the overall burden of care decreased, under-fifty PD procedures between 2006 and 2009 showed an upward trend (APC=27.01%). SD processes showed a non-significant upward trend (APC=1.92%) between 2005 and 2020. The upward trend in silicosis care processes in people under fifty years of age since 2005 confirms the healthcare impact of the re-emergence of silicosis in Spain. The associated burden of care constitutes a present and future public health problem given the decreasing age of those affected.


  • Open Access

    Medical costs of asbestos-related diseases in Spain between 2004 and 2011

    by Montserrat García-Gómez, Rosa Urbanos Garrido, Rosario Castañeda López, Alfredo Menéndez-Navarro

    The objective of this article was to estimate the medical costs derived from malignant ARD treatment in the Spanish National Health System (NHS) between 2004 and 2011. Estimation of direct healthcare costs was based on national primary data on the cost of specialized care for inpatients and outpatients treated at NHS hospitals and on national and regional secondary data on costs of primary healthcare and pharmaceutical prescriptions. A prevalence approach was used to estimate the overall burden of ARDs. Direct medical costs of 37,557 ARDs attended in Spanish NHS facilities in 2004-2011 were estimated at 464 million euros; specialist care accounted for 50.9% of total costs, primary healthcare 10.15%, and drug prescription 38.9%. The cost was 27.8-fold higher in males than in females. Bronchopulmonary cancers represented the greatest healthcare cost, 281 million euros. The cost of delivering healthcare to ARDs victims in Spain has a negative economic impact on the NHS due to the gross under-recognition of occupational victims under the Spanish National Insurance System.


  • Open Access

    Nuclear Energy in the Public Sphere: Anti-Nuclear Movements vs. Industrial Lobbies in Spain (1962–1979)

    by Luis Sánchez-Vázquez, Alfredo Menéndez-Navarro


  • Asbestos-related occupational cancers compensated under the Spanish National Insurance System, 1978–2011

    by Montserrat García-Gómez, Alfredo Menéndez-Navarro, Rosario Castañeda López

    Background: In 1978, asbestos-related occupational cancers were added to the Spanish list of occupational diseases. However, there are no full accounts of compensated cases since their inclusion. Objective: To analyze the cases of asbestos-related cancer recognized as occupational in Spain between 1978 and 2011. Methods: Cases were obtained from the Spanish Employment Ministry. Specific incidence rates by year, economic activity, and occupation were obtained. We compared mortality rates of mesothelioma and bronchus and lung cancer mortality in Spain and the European Union. Results: Between 1978 and 2011, 164 asbestos-related occupational cancers were recognized in Spain, with a mean annual rate of 0.08 per 10(5) employees (0.13 in males, 0.002 in females). Under-recognition rates were an estimated 93.6% (males) and 99.7% (females) for pleural mesothelioma and 98.8% (males) and 100% (females) for bronchus and lung cancer. In Europe for the year 2000, asbestos-related occupational cancer rates ranged from 0.04 per 10(5) employees in Spain to 7.32 per 10(5) employees in Norway. Conclusions: These findings provide evidence of gross under-recognition of asbestos-related occupational cancers in Spain. Future work should investigate cases treated in the National Healthcare System to better establish the impact of asbestos on health in Spain.


  • Reviews

    by Anna Marie Roos, Georgiana D. Hedesan, Robert Fox, Bernadette Bensaude-Vincent, Jeffrey Allan Johnson, Duncan Wilson, Robert G. W. Kirk, Alfredo Menéndez-Navarro, William H. Brock